Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Kinder Morgan Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Kinder Morgan Inc trades at $32.41 (market cap $71.46B). The key difference: Kinder Morgan Inc is far larger — about 86.5× Amphastar Pharmaceuticals Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KMI | |
|---|---|---|
Market Cap | $826.08M | $71.46B |
Sector | Health | Energy |
52-Week High | $30.81 | $34.31 |
52-Week Low | $16.87 | $25.84 |
Enterprise Value | $1.22B | $103.34B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Kinder Morgan (KMI) trades at $32.12, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $0.48 EPS, and maintains a solid dividend. Revenue grew to $16.94B in 2025, with net income margin improving to 18.92%. Recent news highlights KMI's exposure to natural gas infrastructure growth and stable cash flows from fee-based contracts.
KMI offers a balanced risk-reward profile with steady cash flow and dividend appeal, supported by a $10.1B project backlog. Risks include commodity price volatility and high debt levels. Analyst consensus is mixed but leans positive, with 47% buy ratings. The stock's valuation at a P/E of 21.56 is reasonable given earnings growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
